CXCL8 and colorectal carcinoma: In this context, targeting of IL-8 and its cognate receptors might be developed into a potentially effective treatment strategy, as suggested, for example, by a recent phase I trial with an anti-IL-8 mAb which, in monotherapy, achieved disease control (for 3.5, 4.5, and 7 months) even with 3/4 advanced, refractory CRC patients [37].